Peripheral targeting of TNFR1 and Lcn2 as treatments for Alzheimer’s disease



We recently found that intraperitoneal application of the TNF receptor 2 agonist: Star 2 (1), improved spatial learning and abrogated Amyloid plaque formation in a J20 Alzheimer mouse model (1) (see figure 1). We want to test the hypothesis whether systemically blocking TNFR1 and Lcn2 can also improve AD related cognitive dysfunction and pathology.
Effectieve start/einddatum01/04/202201/04/2026